|
On a consolidated basis, net sales fell 2.8% to Rs 443.56 crore in Q2 September 2020 over Q2 September 2019. Profit before tax (PBT) fell 2.1% to Rs 99.33 crore during the period under review. Tax expense stood at Rs 25.4 crore in Q2 September 2020, steeply higher than Rs 7.74 crore in Q2 September 2019.
EBITDA rose 9.8% year on year to Rs 110.1 crore in Q2 September 2020 from Rs 100.3 crore in Q2 September 2019. EBITDA margin grew to 24.8% in Q2 September 2020 from 22% in Q2 September 2019. The result was announced after market hours yesterday, 10 November 2020.
Commenting on business outlook, Nikhil Chopra, CEO, JB Chemicals & Pharmaceuticals said, "I am delighted to be at the helm of JBCPL, a company with a strong business model and multipronged drivers of long-term growth. With management control transitioning to KKR and the new management team coming on board, the company is uniquely positioned to capitalize on opportunities in formulations, contract manufacturing and API's. Our future path to value creation will focus on Portfolio ramp up and building bigger brands in domestic formulations, Strengthening of R&D to support filings & dossier registrations in regulated and semi regulated markets, Expansion of lozenges platform to support our CMO business and Deeper focus on Business Development and Strategic Partnerships along with synergistic acquisitions. So far, we have seen strong operating performance across business units first half of FY21. As we move into the second half of the financial year, we look forward to formulating and kickstarting several initiatives that we believe will enhance stakeholder value in line with potential."
J B Chemicals & Pharmaceuticals is a pharmaceutical company manufacturing & marketing a diverse range of pharmaceutical formulations, herbal remedies and APIs.
|